Screener
Ionis Pharmaceuticals IONS Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $$2,994,501 | 3,523,836 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $$47,704 | 28,082 |
| Accrued compensation | 50,293 | 116,236 |
| Accrued liabilities | 115,778 | 106,089 |
| Income taxes payable | 2,877 | 2,713 |
| 0 percent convertible senior notes due April 2026, net | - | 431,948 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's accounts payable?
- Ionis Pharmaceuticals (IONS) reported accounts payable of $47.7M in Q2 2026.
- How has Ionis Pharmaceuticals's accounts payable changed year-over-year?
- Ionis Pharmaceuticals's accounts payable increased by 109.2% year-over-year, from $22.8M to $47.7M.
- What is the long-term trend for Ionis Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's accounts payable has grown at a 10.3% compound annual growth rate (CAGR), from $17.2M to $28.08M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Ionis Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude